1 not yet recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Therakos LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure methoxsalen, Extracorporeal photopheresis (ECP), Vedolizumab - Colitis, Hepatitis | Phase 2 | Not yet recruiting | Therakos LLC | 112 | 2026-07-01 | 2026-06-02 |
| EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis Methoxsalen, Infliximab, Vedolizumab - Immune-related Colitis | Phase 2 | Withdrawn | Therakos LLC | 2025-12-15 | 2025-12-26 |
Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Colitis (1) · Hepatitis (1)
Infliximab (2) · Methoxsalen (2) · vedolizumab (2) · Azathioprine (1) · Mycophenolic Acid (1) · Photopheresis (1)
United States (1)